Private Advisor Group LLC lifted its holdings in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 9.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 22,672 shares of the company's stock after purchasing an additional 1,940 shares during the period. Private Advisor Group LLC's holdings in Moderna were worth $3,239,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Keybank National Association OH lifted its position in Moderna by 22.1% during the first quarter. Keybank National Association OH now owns 2,877 shares of the company's stock valued at $496,000 after acquiring an additional 521 shares during the last quarter. Oliver Lagore Vanvalin Investment Group purchased a new stake in Moderna during the first quarter valued at approximately $30,000. Fieldpoint Private Securities LLC lifted its position in Moderna by 103.8% during the first quarter. Fieldpoint Private Securities LLC now owns 214 shares of the company's stock valued at $37,000 after acquiring an additional 109 shares during the last quarter. Metis Global Partners LLC lifted its position in Moderna by 79.5% during the first quarter. Metis Global Partners LLC now owns 5,530 shares of the company's stock valued at $953,000 after acquiring an additional 2,450 shares during the last quarter. Finally, Ellis Investment Partners LLC lifted its position in Moderna by 112.5% during the first quarter. Ellis Investment Partners LLC now owns 425 shares of the company's stock valued at $73,000 after acquiring an additional 225 shares during the last quarter. Hedge funds and other institutional investors own 60.76% of the company's stock.

Moderna Stock Down 3.2 %

NASDAQ:MRNA opened at $119.69 on Tuesday. The firm has a market capitalization of $47.61 billion, a P/E ratio of 3.65, a PEG ratio of 0.72 and a beta of 1.69. Moderna, Inc. has a 1-year low of $115.61 and a 1-year high of $434.00. The company's fifty day moving average price is $150.91 and its 200-day moving average price is $150.73. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.99 and a quick ratio of 1.71.

Analyst Ratings Changes

A number of research firms recently commented on MRNA. Argus decreased their target price on shares of Moderna from $180.00 to $150.00 and set a "buy" rating for the company in a research report on Wednesday, September 14th. Morgan Stanley decreased their target price on shares of Moderna from $199.00 to $197.00 and set an "equal weight" rating for the company in a research report on Thursday, August 4th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a "hold" rating to a "buy" rating and raised their price target for the stock from $155.00 to $165.00 in a report on Wednesday, September 7th. Finally, SVB Leerink raised their price target on shares of Moderna from $70.00 to $77.00 and gave the stock an "underperform" rating in a report on Monday, August 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $211.08.

Insider Activity at Moderna

In related news, President Stephen Hoge sold 5,000 shares of the firm's stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $168.88, for a total transaction of $844,400.00. Following the sale, the president now owns 1,624,231 shares in the company, valued at $274,300,131.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Stephane Bancel sold 40,000 shares of the firm's stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $124.75, for a total transaction of $4,990,000.00. Following the sale, the chief executive officer now owns 5,411,946 shares in the company, valued at $675,140,263.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Stephen Hoge sold 5,000 shares of the firm's stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $168.88, for a total transaction of $844,400.00. Following the sale, the president now owns 1,624,231 shares in the company, valued at approximately $274,300,131.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 648,048 shares of company stock worth $101,158,042. 17.30% of the stock is owned by company insiders.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

• Get a free copy of the StockNews.com research report on Moderna (MRNA)
• MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
• MO Money: Why Altria Group Stock is Rallying
• Is the Market Overreacting with Shopify Stock?
• Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
• Three Consumer Stocks That Could Outperform In Q4

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Get Rating).

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.